View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsSelectimmune Pharma 将来の成長Future 基準チェック /06現在、 Selectimmune Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長37.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 26Selectimmune Pharma AB (publ) to Report Q1, 2024 Results on Nov 16, 2023Selectimmune Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 16, 2023お知らせ • Nov 25Selectimmune Pharma AB (publ) Elects Magnus Nylén as New Member of BoardSelectimmune Pharma AB (publ) announced that at its AGM held on November 23, 2022, the shareholders elected Magnus Nylén as new member of board.お知らせ • Nov 17+ 1 more updateSelectimmune Pharma AB (publ) to Report Q2, 2023 Results on Feb 23, 2023Selectimmune Pharma AB (publ) announced that they will report Q2, 2023 results on Feb 23, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Acting CEO, Chief Medical Officer & Board Member Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Nov 15Selectimmune Pharma Has Successfully Completed Preparations to Start A Controlled Clinical Trial in Patients with Bladder Pain SyndromeSelectImmune Pharma has successfully completed preparations to start a controlled clinical trial in patients with bladder pain syndrome (severe pain in the bladder). They can now announce that the study has started and the first patient has been included in the study. The patients must be treated with the drug Kineret, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA). Patients with bladder pain syndrome have severe pain of unknown cause. Many different treatments have been tried without lasting positive effects. The development of new, more precise drugs has been hampered by the fact that the cause of the pain is unknown. Treatment with IL1RA "off-label" has previously shown positive results in the clinic. Kineret is an IL-1 receptor antagonist that neutralizes the biological activity of the two proinflammatory cytokines IL-1 a and IL-1 b. In the previously treated patients, the pain was reduced and the quality of life increased in this severely disabled patient group. Several patients were able to return to a more normal life. The placebo-controlled study is important to evaluate the treatment effect with greater precision. The study will include a larger number of patients and clinical centers, to address the treatment effect. Research has previously shown that pain is greatly reduced by IL-1RA treatment, even in an animal model. The study will initially include two centers in Sweden, which have extensive experience with this particular patient group. The company has established the study organization in Sweden, received permission from the Swedish Medicines Agency and the Ethical Review Authority and gained access to placebos through an agreement with Sobi (Swedish Orphan Biovitrum). The possibility of treating this patient group is of great medical interest.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Board Member & CMO Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 27Selectimmune Pharma AB (publ) Appoints Gabriela Godaly as Acting CEOSelectimmune Pharma AB (publ) announced that Gabriela Godaly will take the role as acting CEO of SelectImmune Pharma until a new permanent CEO has been appointed. She was appointed Chief Medical Officer of SelectImmune Pharma in 2020 and has served on the Board of Directors since 2019.お知らせ • Apr 26Selectimmune Pharma AB (publ) Receives Approval to Conduct A Placebo-Controlled Clinical Study of Bladder PainSelectimmune Pharma AB (publ) announced that the Swedish Medical Products Agency (Läkemedelsverket) has approved the application to conduct a placebo-controlled clinical study using IL1-RA for the treatment of Bladder Pain Syndrome. Bladder pain syndrome is a highly painful chronic condition that severely impairs the quality of life of affected patients. Numerous therapeutic approaches have been tested, but currently, no specific therapies are available. Regular painkillers, or even morphine fails to provide adequate symptom relief and even after surgical removal of damaged parts of the bladder, the pain often returns. Company has recently reported positive treatment effects in this patient group, using the IL1-a and ß receptor antagonist (IL1-RA) anakinra, reducing patient symptoms and increasing quality of life. The study also reported positive long-term effects, in patients who continue treatment. SelectImmune Pharma is now proceeding with a randomized, placebo-controlled study of IL1-RA in patients with bladder pain syndrome. The company has received clinical trial authorization from the Swedish Medical Products Agency (Läkemedelsverket). The study is planned to involve several clinical sites.お知らせ • Mar 30Selectimmune Pharma AB to Conduct Clinical Trials in Cystitis and Bladder Pain SyndromeSelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi) to buy Kineret (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome. Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation and infection in animal models of cystitis and SelectImmune Pharma is now pursuing clinical trials to further assess the clinical efficacy in these areas. Kineret (anakinra) is a trademark of Sobi, who markets the drug for various inflammatory conditions, whereas SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and bladder pain syndrome specifically. The agreement defines that SelectImmune Pharma will conduct clinical trials in these areas with Sobi as the provider of drug and placebo. The parties have the intention to discuss a potential commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.お知らせ • Mar 28Selectimmune Pharma AB (publ) Announces Resignation of Ann Gidner as CEOSelectImmune Pharma AB's CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.お知らせ • Feb 25+ 3 more updatesSelectimmune Pharma AB (publ) to Report Q1, 2023 Results on Nov 16, 2022Selectimmune Pharma AB (publ) announced that they will report Q1, 2023 results on Nov 16, 2022お知らせ • Feb 02SelectImmune Pharma AB Files Important Patent Application for Acute PyelonephritisSelectImmune Pharma AB has filed for patent protection over a range of new agents that show surprising levels of activity in treatment of pyelonephritis. This new patent application adds to SelectImmune Pharma's expanding range of intellectual property rights in the pharmaceutical sector, specifically for treating bacterial infections. Acute pyelonephritis or kidney infection, is a severe and common form of urinary tract infection, caused by bacteria that directly infect the kidneys. In about 30% of adults with acute pyelonephritis, bacteria invade the blood stream, causing urosepsis and without appropriate treatment, mortality is high. Acute pyelonephritis is also common in childhood, and may cause long-term problems by damaging renal tissue. Following extensive research at Lund University into new treatment options for acute pyelonephritis, efficient new approaches have now been identified and the therapeutic effects confirmed in animal models, strengthening the commitment to develop these substances for future clinical use.分析記事 • Jul 21We're Interested To See How Selectimmune Pharma (NGM:SELECT B) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Mar 24Selectimmune Pharma (NGM:SELECT B) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is New 90 Day High Low • Jan 28New 90-day high: kr16.30The company is up 24% from its price of kr13.12 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.Is New 90 Day High Low • Dec 23New 90-day high: kr15.60The company is up 5.0% from its price of kr14.90 on 23 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 5.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: kr12.28The company is down 9.0% from its price of kr13.46 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.お知らせ • Aug 14Selectimmune Pharma AB (publ) announced that it has received SEK 40 million in fundingSelectimmune Pharma AB (publ) (NGM:SELECT B) announced private placement of common shares for gross proceeds of SEK 40,000,000 in March 2019. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Selectimmune Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NGM:SELECT B - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2023N/A-9-9-9N/A12/31/2022N/A-9-10-10N/A9/30/2022N/A-12-17-17N/A6/30/2022N/A-14-15-15N/A3/31/2022N/A-16-15-15N/A12/31/2021N/A-15-13-13N/A9/30/2021N/A-14-11-11N/A6/30/2021N/A-13-11-11N/A3/31/2021N/A-9-10-8N/A12/31/2020N/A-9-9-7N/A9/30/2020N/A-8-7-5N/A6/30/2020N/A-8-12-10N/A3/31/2020N/A-10-11-11N/A12/31/2019N/A-9-10-10N/A6/30/2019N/A-4-2-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SELECT Bの予測収益成長が 貯蓄率 ( 0.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SELECT Bの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SELECT Bの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SELECT Bの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SELECT Bの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SELECT Bの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/11 04:41終値2023/08/08 00:00収益2023/03/31年間収益2022/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Selectimmune Pharma AB (publ) これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 26Selectimmune Pharma AB (publ) to Report Q1, 2024 Results on Nov 16, 2023Selectimmune Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 16, 2023
お知らせ • Nov 25Selectimmune Pharma AB (publ) Elects Magnus Nylén as New Member of BoardSelectimmune Pharma AB (publ) announced that at its AGM held on November 23, 2022, the shareholders elected Magnus Nylén as new member of board.
お知らせ • Nov 17+ 1 more updateSelectimmune Pharma AB (publ) to Report Q2, 2023 Results on Feb 23, 2023Selectimmune Pharma AB (publ) announced that they will report Q2, 2023 results on Feb 23, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Acting CEO, Chief Medical Officer & Board Member Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Nov 15Selectimmune Pharma Has Successfully Completed Preparations to Start A Controlled Clinical Trial in Patients with Bladder Pain SyndromeSelectImmune Pharma has successfully completed preparations to start a controlled clinical trial in patients with bladder pain syndrome (severe pain in the bladder). They can now announce that the study has started and the first patient has been included in the study. The patients must be treated with the drug Kineret, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA). Patients with bladder pain syndrome have severe pain of unknown cause. Many different treatments have been tried without lasting positive effects. The development of new, more precise drugs has been hampered by the fact that the cause of the pain is unknown. Treatment with IL1RA "off-label" has previously shown positive results in the clinic. Kineret is an IL-1 receptor antagonist that neutralizes the biological activity of the two proinflammatory cytokines IL-1 a and IL-1 b. In the previously treated patients, the pain was reduced and the quality of life increased in this severely disabled patient group. Several patients were able to return to a more normal life. The placebo-controlled study is important to evaluate the treatment effect with greater precision. The study will include a larger number of patients and clinical centers, to address the treatment effect. Research has previously shown that pain is greatly reduced by IL-1RA treatment, even in an animal model. The study will initially include two centers in Sweden, which have extensive experience with this particular patient group. The company has established the study organization in Sweden, received permission from the Swedish Medicines Agency and the Ethical Review Authority and gained access to placebos through an agreement with Sobi (Swedish Orphan Biovitrum). The possibility of treating this patient group is of great medical interest.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Board Member & CMO Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 27Selectimmune Pharma AB (publ) Appoints Gabriela Godaly as Acting CEOSelectimmune Pharma AB (publ) announced that Gabriela Godaly will take the role as acting CEO of SelectImmune Pharma until a new permanent CEO has been appointed. She was appointed Chief Medical Officer of SelectImmune Pharma in 2020 and has served on the Board of Directors since 2019.
お知らせ • Apr 26Selectimmune Pharma AB (publ) Receives Approval to Conduct A Placebo-Controlled Clinical Study of Bladder PainSelectimmune Pharma AB (publ) announced that the Swedish Medical Products Agency (Läkemedelsverket) has approved the application to conduct a placebo-controlled clinical study using IL1-RA for the treatment of Bladder Pain Syndrome. Bladder pain syndrome is a highly painful chronic condition that severely impairs the quality of life of affected patients. Numerous therapeutic approaches have been tested, but currently, no specific therapies are available. Regular painkillers, or even morphine fails to provide adequate symptom relief and even after surgical removal of damaged parts of the bladder, the pain often returns. Company has recently reported positive treatment effects in this patient group, using the IL1-a and ß receptor antagonist (IL1-RA) anakinra, reducing patient symptoms and increasing quality of life. The study also reported positive long-term effects, in patients who continue treatment. SelectImmune Pharma is now proceeding with a randomized, placebo-controlled study of IL1-RA in patients with bladder pain syndrome. The company has received clinical trial authorization from the Swedish Medical Products Agency (Läkemedelsverket). The study is planned to involve several clinical sites.
お知らせ • Mar 30Selectimmune Pharma AB to Conduct Clinical Trials in Cystitis and Bladder Pain SyndromeSelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi) to buy Kineret (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome. Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation and infection in animal models of cystitis and SelectImmune Pharma is now pursuing clinical trials to further assess the clinical efficacy in these areas. Kineret (anakinra) is a trademark of Sobi, who markets the drug for various inflammatory conditions, whereas SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and bladder pain syndrome specifically. The agreement defines that SelectImmune Pharma will conduct clinical trials in these areas with Sobi as the provider of drug and placebo. The parties have the intention to discuss a potential commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.
お知らせ • Mar 28Selectimmune Pharma AB (publ) Announces Resignation of Ann Gidner as CEOSelectImmune Pharma AB's CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.
お知らせ • Feb 25+ 3 more updatesSelectimmune Pharma AB (publ) to Report Q1, 2023 Results on Nov 16, 2022Selectimmune Pharma AB (publ) announced that they will report Q1, 2023 results on Nov 16, 2022
お知らせ • Feb 02SelectImmune Pharma AB Files Important Patent Application for Acute PyelonephritisSelectImmune Pharma AB has filed for patent protection over a range of new agents that show surprising levels of activity in treatment of pyelonephritis. This new patent application adds to SelectImmune Pharma's expanding range of intellectual property rights in the pharmaceutical sector, specifically for treating bacterial infections. Acute pyelonephritis or kidney infection, is a severe and common form of urinary tract infection, caused by bacteria that directly infect the kidneys. In about 30% of adults with acute pyelonephritis, bacteria invade the blood stream, causing urosepsis and without appropriate treatment, mortality is high. Acute pyelonephritis is also common in childhood, and may cause long-term problems by damaging renal tissue. Following extensive research at Lund University into new treatment options for acute pyelonephritis, efficient new approaches have now been identified and the therapeutic effects confirmed in animal models, strengthening the commitment to develop these substances for future clinical use.
分析記事 • Jul 21We're Interested To See How Selectimmune Pharma (NGM:SELECT B) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Mar 24Selectimmune Pharma (NGM:SELECT B) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Is New 90 Day High Low • Jan 28New 90-day high: kr16.30The company is up 24% from its price of kr13.12 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Dec 23New 90-day high: kr15.60The company is up 5.0% from its price of kr14.90 on 23 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 5.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: kr12.28The company is down 9.0% from its price of kr13.46 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
お知らせ • Aug 14Selectimmune Pharma AB (publ) announced that it has received SEK 40 million in fundingSelectimmune Pharma AB (publ) (NGM:SELECT B) announced private placement of common shares for gross proceeds of SEK 40,000,000 in March 2019.